Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BI 3821001 in Healthy Male Participants
NCT07526194Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3821001 (10 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any treatment-emergent adverse event assessed as drug-related at 60 days. Started Apr 2026; status: completed.
02
Drugs
BI 3821001
Beyond the preview
Go deeper on NCT07526194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07526194.